

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 October 2020 (08.10.2020)



(10) International Publication Number
WO 2020/201568 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *C07K 17/06* (2006.01)
A61K 31/7115 (2006.01) *A61P 35/00* (2006.01)
A61K 47/34 (2017.01) *C07K 16/32* (2006.01)
C12N 15/117 (2010.01) *C07K 16/28* (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2020/059689

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(22) International Filing Date:

03 April 2020 (03.04.2020)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19167141.1 03 April 2019 (03.04.2019) EP

(71) Applicant: **TARGIMMUNE THERAPEUTICS AG**
[CH/CH]; Hochbergerstrasse 60c, 4057 Basel (CH).

(72) Inventors: **BROKA, Derrick**; Zürichstrasse 7, 6004 Luzern (CH). **COLECCHIA, David**; St. Alban Ring 250, 4052 Basel (CH). **D'AMICO, Lucia**; Neuhausstrasse 30, 4057 Basel (CH). **KITAS, Eric**; Eichbergweg 4, 4147 Aesch (CH). **LEVITZKI, Alexander**; 11/6 Yehuda Burla Street Nayot, 93714 Jerusalem (IL). **POMBO-VILLAR, Esteban**; Höhenweg 63, 4102 Binningen (CH). **SHIR, Alexei**; 7/7 Shmuel Tamir Street, 9781207 Jerusalem (IL). **ZIGLER, Maya**; Hirzbodenweg 17, 4052 Basel (CH). **BAJIC, Davor**; Beim Letziturm 16, 4052 Basel (CH). **JARZEBINSKA, Anita**; Lothringerstrasse 108, 4056 Basel (CH).

(74) Agent: **SPERRLE, Martin**; Latscha Schöllhorn Partner AG Grellingerstrasse 60, 4052 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: IMMUNOTHERAPY FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention relates to a kit-of-parts comprising and a composition comprising a polyplex comprising a double stranded RNA (dsRNA) and a polymeric conjugate comprising a polyethyleneimine (PEI), one or more polyethylene glycol (PEG) moieties and one or more targeting moieties, and wherein each of said one or more targeting moieties is capable of binding to a cancer antigen; and at least one antibody, wherein said at least one antibody is capable of modulating an immune checkpoint protein. Further the invention relates to this composition or kit-of-parts for use in the treatment of cancer.



WO 2020/201568 A1